Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Elraglusib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Actuate Expands Pipeline with Elraglusib Ph 1/2 Program in Cancer
    Actuate Expands Pipeline with Elraglusib Ph 1/2 Program in Cancer

    21 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/21/3222807/0/en/Actuate-Therapeutics-Announces-Plans-to-Expand-Clinical-Pipeline-Advancing-Elraglusib-Tablet-into-a-Phase-1-2-Clinical-Program-in-Refractory-Cancers.html

    GLOBENEWSWIRE
    21 Jan 2026
    Share Share
    Actuate Therapeutics Shows Extended Survival Benefit
    Actuate Therapeutics Shows Extended Survival Benefit

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216938/0/en/Actuate-Therapeutics-Reports-Positive-Follow-Up-Data-from-its-Randomized-Controlled-Phase-2-Trial-Demonstrating-Extended-Long-Term-Overall-Survival-Benefit-with-Elraglusib-Plus-Che.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    ASCO GI 2026 Selects Actuate's Phase 2 Data for Presentation
    ASCO GI 2026 Selects Actuate's Phase 2 Data for Presentation

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3207741/0/en/Actuate-Therapeutics-Phase-2-Metastatic-Pancreatic-Cancer-Data-Selected-for-Oral-and-Poster-Presentation-at-ASCO-GI-2026.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    Actuate Therapeutics Submits Updated Clinical Data To FDA
    Actuate Therapeutics Submits Updated Clinical Data To FDA

    22 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/22/3153932/0/en/Actuate-Therapeutics-Provides-FDA-with-Updated-Clinical-Data-Package-to-Support-Planned-Regulatory-Interactions-with-FDA-and-EMA-Over-the-Coming-Months.html

    GLOBENEWSWIRE
    22 Sep 2025
    Share Share
    Actuate, Incyte, Pitt to Test Elraglusib in Pancreatic Cancer
    Actuate, Incyte, Pitt to Test Elraglusib in Pancreatic Cancer

    06 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/06/3128350/0/en/Actuate-Therapeutics-To-Collaborate-with-Incyte-Corporation-and-the-University-of-Pittsburgh-on-Clinical-Trial-of-Elraglusib-in-Combination-with-Retifanlimab-and-mFOLFIRINOX-in-Pat.html

    GLOBENEWSWIRE
    06 Aug 2025
    Share Share
    Actuate's Pancreatic Cancer Drug Boosts Survival by 3 Months
    Actuate's Pancreatic Cancer Drug Boosts Survival by 3 Months

    03 Jun 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/asco-actuates-pancreatic-cancer-drug-boost-survival-3-months-phase-2-study

    FIERCE BIOTECH
    03 Jun 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.